Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Michael Nassif, MD, MSc
Anjali Owens, MD
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Ahmad Masri, MD, MS
Safety in oHCM Therapy: How and When to Transition Treatment?
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Pam R. Taub, MD, FACC, FASPC
Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
Roxana Mehran, MD, FSCAI
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
James Burton, DM, FRCP
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
Patrick Rossignol, MD, PhD
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Potassium Binders: Safety Comes First!
Potassium Binders in Practice: Clinical Trial Evidence
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up